UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/764,215	01/23/2004	Boon Peng Chew	P142M	9145	
27752 THE PROCTE	7590 11/29/2007 ER & GAMBLE COMPAN	EXAMINER			
INTELLECTUAL PROPERTY DIVISION - WEST BLDG.			VAKILI, ZOHREḤ		
	ON HILL BUSINESS CENTER - BOX 412 ENTER HILL AVENUE		ART UNIT	PAPER NUMBER	
CINCINNATI	, OH 45224		1614		
			MAIL DATE	DELIVERY MODE	
			MAILDATE	DELIVERT MODE	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

•							
		Application No.	Applicant(s)				
		10/764,215	CHEW ET AL.				
Office Action S	Summary	Examiner	Art Unit				
		Zohreh Vakili	1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
	FROM THE MAILING DA under the provisions of 37 CFR 1.13 ing date of this communication. ive, the maximum statutory period we ided period for reply will, by statute, than three months after the mailing	ATE OF THIS COMMUNICATE OF THIS COMMUNICATE OF THIS COMMUNICATE OF THE O	ATION. Ny be timely filed HS from the mailing date of this of the NDONED (35 U.S.C. § 133).				
Status							
1) Responsive to commu	unication(s) filed on 10 Se	eptember 2007.					
2a) This action is FINAL.	·						
	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) Claim(s) <u>1-17</u> is/are p	ending in the application.						
4a) Of the above claim(s) 10-17 is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠ Claim(s) <u>1-9</u> is/are rej							
7) Claim(s) is/are	•	election requirement					
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is ob	•						
10) The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
Notice of References Cited (PTO Notice of Draftsperson's Patent I			ımmary (PTO-413) /Mail Date				
Notice of Draftsperson's Patent I Information Disclosure Statemen Paper No(s)/Mail Date			ormal Patent Application				

10/764,215

Art Unit: 1614

DETAILED ACTION

Claims 1-17 are presented for examination.

Status of the Case

The Amendments and Remarks, filed September 10, 2007 have been received and entered into the application. Accordingly, claim 1 has been amended and claims 10-17 has been withdrawn.

Applicant's arguments, filed September 10, 2007, have been fully considered but they are not deemed to be persuasive. Rejections not reiterated from previous Office Actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set of rejections presently being applied to the instant application.

Maintained Claim Rejections - 35 USC § 112

The term "less than about" in claims 2 and 3 is a relative term which renders the claim indefinite. The term "less than about" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The phrase

Application/Control Number:

10/764,215 Art Unit: 1614

"less than about" consists of two very broad and indefinite limitation. The phrase "less than about" fails to set forth a lower limit for the concentration of the agent. Such phrase covers 0% of the agent in the composition. The word "less than" conflicts with the word "about", both of them cannot be used in the same phrase. Further the term "less than about" contradicts with claim 1 which indicates the composition comprises astaxanthin, where such a phrase covers 0% of the agent in the composition.

Applicant's remarks were fully considered but were not persuasive. Therefore, the rejection under 35 USC § 112 is maintained.

Maintained Claim Rejections - 35 USC § 102

Claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Oliveira et al. (US Pub. No. 2003/0157239 A1).

The rejection of claims 1-9 are rejected under 35 U.S.C. 102(b) as being anticipated by Oliveira et al. (US Pub. No. 2003/0157239 A1) has been maintained for the reasons stated in the prior Office Action April 9, 2007 and further in view of the following remarks.

Response to Arguments

Applicant has amended claim 1 to provide that the composition may attenuate inflammation, enhance immune response, enhance longevity, or combinations thereof.

Applicant argues that Oliveira et al. fails to teach a composition that may attenuate

Application/Control Number:

10/764,215 Art Unit: 161

Art Unit: 1614

inflammation, enhance immune response, enhance longevity, or combinations thereof.

Therefore, Oliveira et al. fails to anticipate the claims.

Examiner does not agree with Applicant's remarks the composition that may attenuate inflammation, enhance immune response, enhance longevity, or combinations thereof are all of intended use. An intended use fails to materially or physically limit the structure of the composition and that so long as the composition of the prior art can perform such a use, then it meets the claims.

Applicant's arguments were considered in its entirety but failed to be persuasive.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136 (a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

10/764,215

Art Unit: 1614

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zohreh Vakili whose telephone number is 571-272-3099. The examiner can normally be reached on 9am to 6:00pm Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ardin Marschel can be reached on 571-272-0718. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Examiner Zohreh Vakili Art Unit 1614

November 20, 2007

SUPERVISORY PATENT EXAMINER

11/25/07